This systematic review evaluates the efficacy of PARP inhibitors in mCRPC patients, suggesting significant benefits in the presence of homologous recombination repair alterations.
Key Points
Combination therapy with PARP inhibitors significantly improves radiographic progression-free survival in mCRPC patients with HRR gene alterations.
Analysis of five phase III randomized controlled trials including 2921 patients confirmed that PARP inhibitors enhance both overall survival and progression-free survival in specific subgroups.
The systematic review focuses on the efficacy of PARP inhibitors as monotherapy and in combination with ARSi, highlighting the need for molecular selection.
Grade ≥3 adverse events were more frequent with PARP inhibitor treatments, indicating a need for careful monitoring and selection of therapies.